Journal
MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS
Volume 1147, Issue -, Pages 221-232Publisher
WILEY-BLACKWELL
DOI: 10.1196/annals.1427.038
Keywords
ketoglutarate dehydrogenase; calcium; Alzheimer's disease; oxidative stress; fibroblasts
Funding
- NIA NIH HHS [AG11921, R01 AG011921, R01 AG014600, R01 AG011921-07, R01 AG019589-05, AG14930, P01 AG014930, AG14600, P01 AG014930-09, R01 AG019589] Funding Source: Medline
- NATIONAL INSTITUTE ON AGING [P01AG014930, R01AG019589, R01AG011921, R01AG014600] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Considerable data support the hypothesis that mitochondrial abnormalities link gene defects and/or environmental insults to the neurodegenerative process. The interaction of oxidants with calcium and the mitochondrial enzymes of the tricarboxylic acid cycle are central to that relationship. Abnormalities that were discovered in brains or fibroblasts front patients with Alzheimer's disease (AD) have been modeled in vitro and in vivo to assess their pathophysiological importance and to determine how they might be reversed. The conclusions are consistent with the hypothesis that the AD-related abnormalities result from oxidative stress. The selection of compounds for reversal is complex because the actions of the relevant compounds vary under different conditions, such as cell redox states and acute versus chronic changes. However, the models that have been developed are useful for testing the effectiveness of the potential medications. The results suggest that the reversal of mitochondria! deficits and a reduction in oxidative stress will reduce clinical and pathological changes and benefit patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available